Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03280264 · OUTCOME

Serum Intact Parathyroid Hormone Level

Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism · Source last updated 2021-05-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
pg/dL
Interval / dispersion
Standard Deviation
Time frame
up to 52 weeks

Groups in this outcome

KHK7580 (2-24 mg)

KHK7580 was orally administered daily.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
KHK7580 (2-24 mg)18

Reported measurements

Source class 1
Values in pg/dL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
KHK7580 (2-24 mg)152.697.3Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        97.3
        value
        152.6
denoms
  1. counts
    1. group Id
      OG000
      value
      18
    units
    Participants
dispersion Type
Standard Deviation
groups
  1. description
    KHK7580 was orally administered daily.
    id
    OG000
    title
    KHK7580 (2-24 mg)
param Type
MEAN
reporting Status
POSTED
time Frame
up to 52 weeks
title
Serum Intact Parathyroid Hormone Level
type
SECONDARY
unit Of Measure
pg/dL

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice